Minerva Neurosciences Q4 net loss widens on non-cash financing charges

Minerva Neurosciences

11/03/2026 11:15

Overview

U.S. CNS drug developer's Q4 net loss widened sharply on non-cash financing charges

Adjusted Q4 net loss also increased year-over-year

Company ended 2025 with $82 mln in cash after $80 mln private placement

Result Drivers

NON-CASH FINANCING CHARGES - Q4 net loss was driven by a $321.5 mln non-cash loss on issuance of convertible preferred stock and warrants related to the October 2025 private placement

HIGHER OPERATING EXPENSES - Q4 R&D and G&A expenses rose year-over-year due to increased consultant and compensation costs

Company press release: ID:nGNX5tLJ9J

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$25.51
Q4 Net Income
-$283.67 mln
Q4 Income from Operations
-$4.98 mln
Q4 Operating Expenses
$4.98 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Minerva Neurosciences Inc is $4.50, about 43.3% below its March 10 closing price of $7.94

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)